Comparing the efficacy of medications for ADHD using meta-analysis

Medications used to treat attention-deficit/hyperactivity disorder (ADHD) have been well researched, but comparisons among drugs are hindered by the absence of direct comparative trials. We analyzed recent published literature on the pharmacotherapy of ADHD to describe the variability of drug-placeb...

Full description

Saved in:
Bibliographic Details
Published in:Medscape general medicine Vol. 8; no. 4; p. 4
Main Authors: Faraone, Stephen V, Biederman, Joseph, Spencer, Thomas J, Aleardi, Megan
Format: Journal Article
Language:English
Published: United States Medscape 05-10-2006
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Medications used to treat attention-deficit/hyperactivity disorder (ADHD) have been well researched, but comparisons among drugs are hindered by the absence of direct comparative trials. We analyzed recent published literature on the pharmacotherapy of ADHD to describe the variability of drug-placebo effect sizes. A literature search was conducted to identify double-blind, placebo-controlled studies of ADHD youth published after 1979. Meta-analysis regression assessed the influence of medication type and study design features on medication effects. Twenty-nine trials met criteria and were included in this meta-analysis. These trials studied 15 drugs using 17 different outcome measures of hyperactive, inattentive, impulsive, or oppositional behavior. The most commonly identified treatments included both methylphenidate and amphetamine compounds. After stratifying trials on the class of drug studied (short-acting stimulant vs long-acting stimulant vs nonstimulant), we found significant drug differences for both study design variables and effect sizes. The differences among the 3 classes of drug remained significant after correcting for study design variables. Uniformity appears to be lacking in how medication effectiveness is assessed and in many study design parameters. Comparing medication effect sizes from different studies will be biased without accounting for variability in study design parameters. Although these differences obscure comparisons among specific medications, they do allow for conclusions about the differential effects of broad classes of medications used to treat ADHD.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Disclosure: Stephen V. Faraone, PhD, has disclosed that he has received grants from Eli Lilly and Company, McNeil Consumer & Specialty Pharmaceuticals, Shire US, Inc., NIMH, NICHHD, and NINDS. He has also disclosed that he has been a consultant for Eli Lilly and Company, McNeil Consumer & Specialty Pharmaceuticals, Shire US, Inc., Noven Pharmaceuticals, and Cephalon, and that he has been on the speaker's bureaus of Eli Lilly and Company, McNeil Consumer & Specialty Pharmaceuticals, Shire US, Inc., and Cephalon.
Disclosure: Joseph Biederman, MD, has disclosed that he receives/d research support from, is/has been a speaker for, or is/has been on the advisory board for the following pharmaceutical companies: Shire, Eli Lilly, Pfizer, McNeil, Abbott, Bristol-Myers Squibb, New River Pharmaceuticals, Cephalon, Janssen, Novartis, UCB Pharma, AstraZeneca, Forest Laboratories, GlaxoSmithKline, and Neurosearch. Other sources of research support/private foundations: Stanley Medical Institute, Lilly Foundation, Prechter Foundation. Government funding: NIMH, NICHD, and NIDA.
Disclosure: Thomas J. Spencer, MD, has disclosed that he receives research support from Shire Laboratories, Inc, Eli Lilly & Company, GlaxoSmithKline, Pfizer Pharmaceutical, McNeil Pharmaceutical, Novartis Pharmaceutical, and NIMH. Dr. Spencer has also disclosed that he is a speaker for GlaxoSmithKline, Eli Lilly & Company, Novartis Pharmaceutical, Wyeth Ayerst, Shire Laboratories Inc, and McNeil Pharmaceutical. Dr. Spencer has also disclosed that he is on the advisory board for Shire Laboratories, Inc, Eli Lilly & Company, GlaxoSmithKline, Pfizer Pharmaceutical, McNeil Pharmaceutical, and Novartis Pharmaceutical.
Disclosure: Megan Aleardi, BA, has disclosed no relevant financial relationships.
ISSN:1531-0132